Oncofertility & Pharmacy: Intervention Evaluation
- A retrospective analysis by Walgreens Specialty pharmacy underscores the importance of fertility preservation as part of comprehensive cancer care.
- Cancer treatments, including chemotherapy, radiation, and surgery, can substantially impact a patient's reproductive abilities.
- The Walgreens study analyzed records of patients receiving oncology treatment between December 2023 and October 2024 to determine the percentage who had a fertility preservation conversation.
A new Walgreens study reveals significant gaps in fertility preservation counseling for cancer patients, highlighting a critical need for intervention. Cancer treatments often lead to infertility, making discussions about fertility preservation essential early on. The research presented at the 2025 Oncology Pharmacists Connect meeting underscores the opportunity for pharmacists to become key figures in bridging interaction gaps and providing vital information about oncofertility options. Pharmacists are uniquely positioned to address this unmet need, offering education and informing patients about available financial aid, as well. News Directory 3 understands the importance of this topic and its impact on patients. Discover what’s next in oncology pharmacy advancements.
Pharmacists Can Improve Fertility Preservation Counseling for Cancer patients
Updated June 11, 2025
A retrospective analysis by Walgreens Specialty pharmacy underscores the importance of fertility preservation as part of comprehensive cancer care. the study,presented at the 2025 Oncology Pharmacists Connect (OPC) meeting in Austin,Texas,examined how ofen cancer patients are offered or receive counseling on fertility preservation when starting treatment. The findings suggest that communication gaps persist between oncologists and patients, creating opportunities for pharmacists to step in and provide crucial data about fertility preservation options.
Cancer treatments, including chemotherapy, radiation, and surgery, can substantially impact a patient’s reproductive abilities. Studies show that 40% to 80% of female cancer patients and 15% to 30% of male cancer patients may face infertility due to their treatment. Therefore, educating patients about available oncofertility techniques at diagnosis is essential.
The Walgreens study analyzed records of patients receiving oncology treatment between December 2023 and October 2024 to determine the percentage who had a fertility preservation conversation. Of the 807 new therapy patients surveyed, 69% felt a conversation wasn’t necessary, 18% said their oncologist hadn’t discussed it, and only 13% consulted with a fertility specialist.
The study reinforces existing data, highlighting the need to counsel newly diagnosed oncology patients about fertility preservation. It also suggests that pharmacists can serve as a valuable resource, addressing the lack of awareness among oncology clinicians and patients. Furthermore, pharmacy teams can inform patients about financial aid options, a significant barrier to fertility preservation.
The 2025 OPC meeting offers attendees a chance to showcase clinical research, explore practice management insights, and discover the latest advancements in oncology pharmacy. The poster session and networking reception promote innovation, collaboration, and professional growth within the oncology pharmacy field.
What’s next
Participants can also attend the Hematology/oncology Pharmacy Association (HOPA) BCOP Program before OPC, featuring continuing education on topics like acute leukemia and cellular therapy.